Figure 1
Overall survival and disease-free survival of CN-AML patients with MLL-PTD evaluated in this study. Fifty percent of the patients are alive and 41% remain disease-free in CR1 beyond 2.5 years.
Overall survival and disease-free survival of CN-AML patients with MLL-PTD evaluated in this study. Fifty percent of the patients are alive and 41% remain disease-free in CR1 beyond 2.5 years.
